Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Cardia Resection For Perforated Gastroesophageal Cancer
Iatrogenic perforation of cancer of the esophagus or the gastroesophageal (GE) junction is a severe complication. Its incidence has increased most likely because of more aggressive palliative endoscopic therapy and the current widespread use of endoscopic ultrasound (EUS) for accurate preoperative staging. Therapy, i.e. conservative versus surgical treatment remains controversial.

Moderates Wooed In House As They Cross Party Lines To Shape Health Legislation
As attempts to gain support for health reform across party lines and from stoic interest groups like the American Medical Association continue, House leaders are seeking to rally centrist members of their own caucus, CQ Politics reports. "House Speaker Nancy Pelosi, whose liberal committee leaders will write health care legislation is attempting to engage moderate Democrats whose votes she will need on the floor."
News of the day
The Formula For Sustainable Healthcare Reform
A new report, released by the Manhattan Institute"s Center for Medical Progress and authored Douglas Holtz-Eakin, the former Director of the Congressional Budget Office, makes the fiscal and political case for bipartisan healthcare reform. Holtz-Eakin addresses dysfunctions in the existing healthcare delivery system; provides solutions to expanding access to affordable private health insurance in an incremental and fiscally responsible manner; and shows how improving market-based options will lead to better consumer access to information on healthcare quality. He argues that the only way to fix our broken healthcare system is through reforms that incentivize competition and pay for quality care.
Health Insurance

NexMed Announces Decision For Anti-Fungal Product

NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® technology, announced the mutual decision with Novartis to terminate the licensing agreement for NM100060, a topically-applied treatment for onychomycosis, commonly known as nail fungus. NexMed entered into the exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060. In addition, NexMed also announced that the results from the comparator study of NM100060 vs. Loceryl, a topical nail lacquer currently marketed in Europe, showed comparable safety and efficacy profiles for the two products in patients with mild to moderate toenail fungus. In the post hoc analysis of patients with mild fungus, NM100060 showed higher efficacy, which was consistent with the results from the two Phase 3 pivotal studies completed by Novartis in 2008. However, the study results were insufficient to support filing for marketing approval. Vivian Liu, NexMed"s Chief Executive Officer said, "There were lessons learned from the studies which warrant further development of this product. We decided that NexMed will proceed with potential new licensing discussions. We have already received inquiries from companies with a focus in dermatology who are interested in commencing discussions." NexMed will host a conference call on July 8, 2009, at 9:00 am EDT to update investors. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 327678 are both required for playback. The conference call will also be Webcast live at URL. The Webcast replay will be available for three months. NexMed


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009